Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.

Chesney J, Imbert-Fernandez Y, Telang S, Baum M, Ranjan S, Fraig M, Batty N.

Melanoma Res. 2018 Mar 20. doi: 10.1097/CMR.0000000000000444. [Epub ahead of print]


Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.

O'Neal J, Clem A, Reynolds L, Dougherty S, Imbert-Fernandez Y, Telang S, Chesney J, Clem BF.

Breast Cancer Res Treat. 2016 Nov;160(1):29-40. Epub 2016 Sep 9.


6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27.

Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O'Neal J, Klarer AC, Clem AL, Telang S, Chesney J.

Cell Death Dis. 2014 Jul 17;5:e1337. doi: 10.1038/cddis.2014.292.


Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3).

Imbert-Fernandez Y, Clem BF, O'Neal J, Kerr DA, Spaulding R, Lanceta L, Clem AL, Telang S, Chesney J.

J Biol Chem. 2014 Mar 28;289(13):9440-8. doi: 10.1074/jbc.M113.529990. Epub 2014 Feb 10.


Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism.

Klarer AC, O'Neal J, Imbert-Fernandez Y, Clem A, Ellis SR, Clark J, Clem B, Chesney J, Telang S.

Cancer Metab. 2014 Jan 23;2(1):2. doi: 10.1186/2049-3002-2-2.


Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.

Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2nd, Klarer AC, Redman R, Miller DM, Trent JO, Telang S, Chesney J.

Mol Cancer Ther. 2013 Aug;12(8):1461-70. doi: 10.1158/1535-7163.MCT-13-0097. Epub 2013 May 14.


Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth.

Telang S, Nelson KK, Siow DL, Yalcin A, Thornburg JM, Imbert-Fernandez Y, Klarer AC, Farghaly H, Clem BF, Eaton JW, Chesney J.

Mol Cancer. 2012 Aug 23;11:60. doi: 10.1186/1476-4598-11-60.


Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells.

Klinge CM, Radde BN, Imbert-Fernandez Y, Teng Y, Ivanova MM, Abner SM, Martin AL.

Mol Cancer Ther. 2011 Nov;10(11):2062-71. doi: 10.1158/1535-7163.MCT-11-0381. Epub 2011 Aug 23.


MUC1/A and MUC1/B splice variants differentially regulate inflammatory cytokine expression.

Imbert-Fernandez Y, Radde BN, Teng Y, Young WW Jr, Hu C, Klinge CM.

Exp Eye Res. 2011 Nov;93(5):649-57. doi: 10.1016/j.exer.2011.08.004. Epub 2011 Aug 16.


Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferation.

Schultz DJ, Wickramasinghe NS, Ivanova MM, Isaacs SM, Dougherty SM, Imbert-Fernandez Y, Cunningham AR, Chen C, Klinge CM.

Mol Cancer Ther. 2010 Mar;9(3):594-605. doi: 10.1158/1535-7163.MCT-09-0978. Epub 2010 Mar 2.

Supplemental Content

Loading ...
Support Center